Evidence map›Paper›PMID 37247873›Full record

Trial reportBMJ global health2023

Effect of a mobile app chatbot and an interactive small-group webinar on COVID-19 vaccine intention and confidence in Japan: a randomised controlled trial.

Takaaki Kobayashi, Hana Tomoi, Yuka Nishina, Ko Harada, Kyuto Tanaka, Shugo Sasaki, Kanako Inaba, Hayato Mitaka, Hiromizu Takahashi, Aly Passanante and 6 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 5 countries.

Takaaki KobayashiDivision of Infectious Diseases, Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA takaaki-kobayashi@uiowa.edu.
Hana TomoiDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Public Health, London, UK.
Yuka NishinaDepartment of General Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Ko HaradaDepartment of Medicine, Mount Sinai Beth Israel Hospital, New York, New York, USA.
Kyuto TanakaDivision of Pulmonary Medicine, Department of Internal Medicine, Nippon Kokan Hospital, Kawasaki, Kanagawa, Japan.
Shugo SasakiDepartment of General Internal Medicine, Saitama Medical University Hospital, Iruma-gun, Saitama, Japan.
Kanako InabaDepartment of Obstetrics and Gynecology, Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku, Tokyo, Japan.
Hayato MitakaDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Hiromizu TakahashiDepartment of General Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Aly PassananteDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Public Health, London, UK.
Eric H Y LauLaboratory of Data Discovery for Health (D24H), Hong Kong SAR, China.
Toshio NaitoDepartment of General Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.ORCID 0000-0003-1646-9930
Heidi LarsonDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Public Health, London, UK.ORCID 0000-0002-8477-7583
Joseph WuLaboratory of Data Discovery for Health (D24H), Hong Kong SAR, China.
Leesa LinDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Public Health, London, UK.ORCID 0000-0003-4123-4762
Yuji YamadaBrookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Juntendo University · JPLondon School of Hygiene & Tropical Medicine · GBUniversity of Washington · USIcahn School of Medicine at Mount Sinai · USKanto Central Hospital · JPLaboratory of Data Discovery for Health · HKMount Sinai Beth Israel · USSaitama Medical University Hospital · JPUniversity of Hong Kong - Shenzhen Hospital · CNUniversity of Iowa Hospitals and Clinics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe investigated the effect of social media-based interventions on COVID-19 vaccine intention (VI) and confidence in Japan.

methodsWe conducted a three-arm randomised controlled trial between 5 November 2021 and 9 January 2022 during a low incidence (<1000/day) of COVID-19 in Japan in the midst of the second and the third waves. Japanese citizens aged ≥20 who had not received any COVID-19 vaccine and did not intend to be vaccinated were randomly assigned to one of the following three groups: (1) a control group, (2) a group using a mobile app chatbot providing information on COVID-19 vaccines and (3) a group using interactive webinars with health professionals. VI and predefined Vaccine Confidence Index (VCI) measuring confidence in the importance, safety and effectiveness were compared before and after the interventions under intention-to-treat principle. Logistic regression models were used to investigate the effect of each intervention on postintervention VI and changes of VCI compared with control.

resultsAmong 386 participants in each group, 359 (93.0%), 231 (59.8%) and 207 (53.6%) completed the postsurvey for the control, chatbot and webinar groups, respectively. The average duration between the intervention and the postsurvey was 32 days in chatbot group and 27 days in webinar group. VI increased from 0% to 18.5% (95% CI 14.5%, 22.5%) in control group, 15.4% (95% CI 10.8%, 20.1%) in chatbot group and 19.7% (95% CI 14.5%, 24.9%) in webinar group without significant difference (OR for improvement=0.8 (95% CI 0.5, 1.3), p=0.33 between chatbot and control, OR=1.1 (95% CI 0.7, 1.6), p=0.73 between webinar and control). VCI change tended to be larger in chatbot group compared with control group without significant difference (3.3% vs -2.5% in importance, OR for improvement=1.3 (95% CI 0.9, 2.0), p=0.18; 2.5% vs 1.9% in safety, OR=1.1 (95% CI 0.7, 1.9), p=0.62; -2.4% vs -7.6% in effectiveness, OR=1.4 (95% CI 0.9, 2.1), p=0.09). Improvement in VCI was larger in webinar group compared with control group for importance (7.8% vs -2.5%, OR=1.8 (95% CI 1.2, 2.8), p<0.01), effectiveness (6.4% vs -7.6%, OR=2.2 (95% CI 1.4, 3.4), p<0.01) and safety (6.0% vs 1.9%, OR=1.6 (95% CI 1.0, 2.6), p=0.08).

conclusionThis study demonstrated that neither the chatbot nor the webinar changed VI importantly compared with control. Interactive webinars could be an effective tool to change vaccine confidence. Further study is needed to identify risk factors associated with decreased vaccine confidence and investigate what intervention can increase VI and vaccine confidence for COVID-19 vaccines. TRIAL REGISTRATION NUMBER: UMIN000045747.

Indexed as

COVID-19Mobile ApplicationsVaccinesCOVID-19 VaccinesHumansIntentionJapanCOVID-19 VaccinesVaccinesCOVID-19SARS-CoV-2social mediavaccinationvaccination hesitancy

Identifiers

PMID37247873
PMCPMC10230336
OpenAlexW4378714328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.